DC Bead (E7040)

Material and We retrospectively evaluated the preoperative predictors of HCC recurrence in 70 patients treated with conventional (n = 16) or doxorubicin-eluting bead TACE (n = 54) before LT. The radiological response and inflammatory markers are predictive of tumour recurrence and allow the proper selection of TACE-treated candidates for LT.

Conclusion The treatment of patients with unresectable HCC with TACE using LifePearl® loaded with doxorubicin or idarubicin showed good tolerance with acceptable toxicity and high tumor response rate that translated into promising PFS, TTUP and OS. Legal entity responsible for the study The authors. Funding Has not received any funding.